Related Experiment Video
Updated: Jul 7, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Abbreviated dose rituximab for immune-mediated hematological disorders
Helen Fairweather1, Annabel Tuckfield, Andrew Grigg
1Department of Clinical Haematology, Royal Melbourne Hospital, Parkville, Victoria, Australia. middlefair@optusnet.com.au
Abstract:
As rituximab, a monoclonal antibody targeting CD20, depletes B cells, there is considerable interest in its use in immune-mediated disorders. The majority of studies employ a four-dose regimen based on practice in lymphoma therapy. We describe our experience with one or two doses of 375 mg/m(2) of rituximab in 12 patients with relapsed and refractory immune-mediated hematological disorders. Eleven patients (92%) achieved a complete remission that has been sustained in 7 for a median of 14.5 (10.5-22) months. Four patients (36%) relapsed after responses of 1-18.5 months. This preliminary experience suggests that one or two doses of rituximab may have response and relapse rates comparable to multidose regimens while potentially providing considerable cost savings. Further prospective studies are planned.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Rational Dosage Regimen: Maintenance Dose and Loading Dose
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady state,...
Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
Rheumatic Heart Disease III: Medical Management
